Choice of Adjuvant Radiotherapy Facility in Major Salivary Gland Cancer
The Laryngoscope · 2024-08 · 134 (8) · 3620-3632
DOI: 10.1002/lary.31352 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 24.02.2024. Verfasst von Aman M Patel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Undergoing surgery and adjuvant radiotherapy (aRT) at the same facility has been associated with higher overall survival (OS) in head and neck squamous cell carcinoma. Our study investigates whether undergoing surgery and aRT at the same academic facility is associated with higher OS in major salivary gland cancer (MSGC).
Methods
The 2006–2018 National Cancer Database was queried for patients with MSGC undergoing surgery at an academic facility and then aRT. Multivariable binary logistic and Cox proportional hazards regression models were implemented.
Results
Of 2801 patients satisfying inclusion criteria, 2130 (76.0%) underwent surgery and aRT at the same academic facility. Residence in a less populated area (adjusted odds ratio [aOR] 1.69, 95% confidence interval [CI] 1.16–2.45), treatment without adjuvant chemotherapy (aOR 1.97, 95% CI 1.41–2.76), and aRT duration (aOR 1.02, 95% CI 1.01–1.04) were associated with undergoing surgery and aRT at different facilities on multivariable logistic regression adjusting for patient demographics, clinicopathologic features, and adjuvant therapy ( p < 0.01). Five‐year OS was higher in patients undergoing surgery and aRT at the same academic facility (68.8% vs. 61.9%, p < 0.001). Undergoing surgery and aRT at different facilities remained associated with worse OS on multivariable Cox regression (aHR 1.41, 95% CI 1.10–1.81, p = 0.007).
Conclusion
Undergoing surgery and aRT at the same academic facility is associated with higher OS in MSGC. Although undergoing surgery and aRT at the same academic facility is impractical for all patients, academic physicians should consider same‐facility treatment for complex patients who would most benefit from clear multidisciplinary communication. Level of Evidence 4 Laryngoscope , 134:3620–3632, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
- Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
- Department of Otolaryngology, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, U.S.A.
ORCID-Profile: Aman M Patel, Afash Haleem, Robert M Brody, Jason A Brant, Ryan M Carey
Zitieren
APA
Patel, A. M., Haleem, A., Maxwell, R., Lukens, J. N., Lin, A., Brody, R. M., Brant, J. A., & Carey, R. M. (2024). Choice of Adjuvant Radiotherapy Facility in Major Salivary Gland Cancer. The Laryngoscope, 134(8), 3620-3632. https://doi.org/10.1002/lary.31352
Vancouver
Patel AM, Haleem A, Maxwell R, Lukens JN, Lin A, Brody RM, et al. Choice of Adjuvant Radiotherapy Facility in Major Salivary Gland Cancer. The Laryngoscope. 2024;134(8):3620-3632. doi:10.1002/lary.31352
BibTeX
@article{Patel2024,
author = {Patel, Aman M and Haleem, Afash and Maxwell, Russell and Lukens, John N and Lin, Alexander and Brody, Robert M and Brant, Jason A and Carey, Ryan M},
title = {Choice of Adjuvant Radiotherapy Facility in Major Salivary Gland Cancer},
journal = {The Laryngoscope},
year = {2024},
volume = {134},
number = {8},
pages = {3620--3632},
doi = {10.1002/lary.31352}
}
EUVIMED